Cargando…
High Viral Specific Antibody Convalescent Plasma Effectively Neutralizes SARS-CoV-2 Variants of Concern
The ongoing evolution of SARS-Co-V2 variants to omicron severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. Covid-19 convalescent plasma (CCP) qualified for high antibody levels effectively reduces immunocompetent outpatient hospitalization. Th...
Autores principales: | Li, Maggie, Beck, Evan J., Laeyendecker, Oliver, Eby, Yolanda, Tobian, Aaron AR, Caturegli, Patrizio, Wouters, Camille, Chiklis, Gregory R., Block, William, McKie, Robert, Joyner, Michael, Wiltshire, Timothy D., Dietz, Allan B., Gniadek, Thomas J., Shapiro, Arell, Yarava, Anusha, Lane, Karen, Hanley, Daniel, Bloch, Evan M., Shoham, Shmuel, Cachay, Edward R., Meisenberg, Barry R., Huaman, Moises A., Fukuta, Yuriko, Patel, Bela, Heath, Sonya L., Levine, Adam C., Paxton, James H., Anjan, Shweta, Gerber, Jonathan M., Gebo, Kelly A., Casadevall, Arturo, Pekosz, Andrew, Sullivan, David J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902868/ https://www.ncbi.nlm.nih.gov/pubmed/35262085 http://dx.doi.org/10.1101/2022.03.01.22271662 |
Ejemplares similares
-
Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
por: Li, Maggie, et al.
Publicado: (2022) -
Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial
por: Baksh, Sheriza N, et al.
Publicado: (2023) -
The Potential Role of Passive Antibody-Based Therapies as Treatments for Monkeypox
por: Bloch, Evan M., et al.
Publicado: (2022) -
How do I implement an outpatient program for the administration of convalescent plasma for COVID‐19?
por: Bloch, Evan M., et al.
Publicado: (2022) -
401. Risk of Post-COVID Conditions Correlates with IL-6 Plasma Levels and Is Reduced by Early Antibody Therapy
por: Fukuta, Yuriko, et al.
Publicado: (2023)